2020-002106-68: FLARE: Favipiravir +/- Lopinavir: A RCT of Early antivirals |
|
|
| Ongoing | 2 | 240 | Europe | Favipiravir, Lopinavir/ritonavir, Tablet, Lopinavir/ritonavir | University College London Comprehensive Clinical Trial Unit, LifeArc | SARS-CoV-2 (Corona virus) infection, COVID-19, Diseases [C] - Virus Diseases [C02] | | | | |
NCT04390152: Safety and Efficacy of Intravenous Wharton's Jelly Derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Due to COVID 19 |
|
|
| Recruiting | 1/2 | 40 | RoW | Wharton's jelly derived Mesenchymal stem cells., Hydroxychloroquine, lopinavir/ritonavir or azithromycin and placebo (standard therapy) | BioXcellerator, Clinical Somer | Acute Respiratory Distress Syndrome | 12/21 | 04/22 | | |
